文献速递疼痛医学

不同丁丙诺啡制剂治疗慢性疼痛:临床研究系统综述

Treatment of Chronic Pain With Various Buprenorphine Formulations: A Systematic Review of Clinical Studies.
PubMed 文献 · Anesth Analg · 2018-01-01

本系统综述检索了截至2017年6月30日的文献,纳入25项随机对照试验,评估5种丁丙诺啡制剂(静脉、舌下、舌下/纳洛酮、颊粘膜、透皮)对慢性疼痛的疗效。结果显示透皮丁丙诺啡在15项研究中有10项显示显著镇痛效果,颊粘膜制剂在3项研究中有2项显示获益,且未报告严重不良事件。结论认为透皮丁丙诺啡是慢性疼痛的有效镇痛选择,颊粘膜制剂也具前景但证据有限。

要点

  • 透皮丁丙诺啡在15项RCT中10项显示显著镇痛效果,为有效选择。
  • 颊粘膜丁丙诺啡在3项研究中2项显示获益,但证据有限。
  • 舌下及静脉丁丙诺啡证据不足,仅6项中1项显示显著获益。

核心结论

  • 透皮丁丙诺啡是慢性疼痛患者的有效镇痛药。
  • 颊粘膜丁丙诺啡基于有限研究也显示前景。

研究设计与样本

  • 系统综述检索PubMed/MEDLINE、EMBASE、Cochrane Database、clinicaltrials.gov和PROSPERO,从建库至2017年6月30日。
  • 采用PICO方法纳入25项随机对照试验,涉及5种丁丙诺啡制剂,对照为阿片类镇痛药或安慰剂。

主要发现

  • 25项研究中14项显示丁丙诺啡对慢性疼痛有临床显著获益。
  • 舌下和静脉丁丙诺啡6项研究中仅1项显示显著镇痛。
  • 舌下丁丙诺啡/纳洛酮仅1项研究显示显著镇痛。
  • 颊粘膜丁丙诺啡3项研究中2项显示显著镇痛。
  • 透皮丁丙诺啡15项研究中10项显示显著镇痛。

临床怎么用

  • 慢性疼痛可优先考虑透皮丁丙诺啡制剂。
  • 颊粘膜丁丙诺啡可作为前景选择,但需更多研究支持。

局限性

  • 舌下及静脉丁丙诺啡相关研究数量有限,证据不充分。
  • 颊粘膜丁丙诺啡的研究数量有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Clinical studies demonstrate that buprenorphine is a pharmacologic agent that can be used for the treatment of various types of painful conditions. This study investigated the efficacy of 5 different types of buprenorphine formulations in the chronic pain population. The literature was reviewed on PubMed/MEDLINE, EMBASE, Cochrane Database, clinicaltrials.gov, and PROSPERO that dated from inception until June 30, 2017. Using the population, intervention, comparator, and outcomes method, 25 randomized controlled trials were reviewed involving 5 buprenorphine formulations in patients with chronic pain: intravenous buprenorphine, sublingual buprenorphine, sublingual buprenorphine/naloxone, buccal buprenorphine, and transdermal buprenorphine, with comparators consisting of opioid analgesics or placebo. Of the 25 studies reviewed, a total of 14 studies demonstrated clinically significant benefit with buprenorphine in the management of chronic pain: 1 study out of 6 sublingual and intravenous buprenorphine, the only sublingual buprenorphine/naloxone study, 2 out of 3 studies of buccal buprenorphine, and 10 out of 15 studies for transdermal buprenorphine showed significant reduction in pain against a comparator. No serious adverse effects were reported in any of the studies. We conclude that a transdermal buprenorphine formulation is an effective analgesic in patients with chronic pain, while buccal buprenorphine is also a promising formulation based on the limited number of studies.

来源:Anesth Analg,查看原文。版权归原作者所有。

引用

  1. Aiyer R, Gulati A, Gungor S, et al. Treatment of Chronic Pain With Various Buprenorphine Formulations: A Systematic Review of Clinical Studies. Anesth Analg. 2018. PMID: 29239947. doi:10.1213/ANE.0000000000002718

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。